Live Breaking News & Updates on Women Cancer Program

Stay updated with breaking news from Women cancer program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dr Brufsky on Unmet Needs and Unanswered Questions in HR+/HER2– Breast Cancer

Adam M. Brufsky, MD, PhD, FACP, discusses remaining questions and unmet needs following the FDA approval of capivasertib in combination with fulvestrant in hormone receptor–positive, HER2-negative breast cancer.
....

Adamm Brufsky , University Of Pittsburgh School Medicine , Breast Cancer Center , Division Of Hematology Oncology , Department Of Medicine , Women Cancer Program , Hillman Cancer Center , Pittsburgh School , Cancer Program , Comprehensive Breast Cancer Center , Cancer Center , Upmc Hillman Cancer Center , Onclive Tv , Breast Cancer ,

Dr Brufsky on the FDA Approval of Capivasertib Plus Fulvestrant in PIK3CA/AKT1/PTEN-Altered HR+/HER2– Breast Cancer

Adam M. Brufsky, MD, PhD, FACP, discusses the significance of the FDA approval of capivasertib in combination with fulvestrant for patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alterations.
....

Adamm Brufsky , Department Of Medicine , University Of Pittsburgh School Medicine , Breast Cancer Center , Division Of Hematology Oncology , Hillman Cancer Center , Women Cancer Program , Pittsburgh School , Cancer Program , Comprehensive Breast Cancer Center , Cancer Center , Upmc Hillman Cancer Center , Onclive Tv , Breast Cancer ,

Dr Basho on Treatment Considerations With ADCs in Breast Cancer

Reva K Basho, MD, discusses the use of antibody-drug conjugates across the spectrum of breast cancer subtypes at the 2023 Bridging the Gaps in Breast Cancer meeting.
....

Ellison Institute , Women Cancer Program , Providence Specialty Medical Group , Revak Basho , Cancer Program , Breast Cancer , Bridging The Gaps In Breast Cancer , Onclive Tv ,

Dr Mina on the Evolution of T-DM1 and T-DXd in HER2+ Breast Cancer

Lida A. Mina, MD, discusses the evolution of the antibody-drug conjugates fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine in HER2-positive breast cancer. ....

United States , Lidaa Mina , Division Of Hematology , Mayo Clinic Comprehensive Cancer Center , Women Cancer Program , Cancer Program , Mayo Arizona Breast Cancer , Medical Oncology , Toxicity Profile , Her2 Positive Breast Cancer , Fam Trastuzumab Deruxtecan Nxki , Ado Trastuzumab Emtansine , Estiny Breast01 , Destiny Breast03 ,

Genomic Testing Is Critical for Improved Personalized Medicine and Treatment Sequencing in Breast Cancer

Lida A. Mina, MD, discusses the evolving role of ADCs across breast cancer subtypes, current data on the use of CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer, and the increased use of genomic testing and NGS to improve the sequencing of agents in triple-negative breast cancer. ....

United States , Lidaa Mina , Karens Anderson , Felipe Batalini , Banner Md Anderson Cancer Center , Division Of Hematology , Women Cancer Program , Mayo Clinic Comprehensive Cancer Center , Cancer Program , Mayo Arizona Breast Cancer , Medical Oncology , Science Summit , Shakeela Bahadur , Cancer Center , Mayo Clinic Comprehensive Cancer , Her2 Positive And Low Breast Cancer , Fam Trastuzumab Deruxtecan Nxki , Personalized Medicine , Next Generation Sequencing , Antibody Drug Conjugates , Cdk4 6 Inhibitors , Hr Positive , Er2 Negative Disease ,